Aqilion’s CEO Sarah Fredriksson is giving a presentation on the topic of finding new interesting projects. EARLY CLINICAL DEVELOPMENT on the 16th of October 2019 at World Trade Center in Stockholm Early_clinical_program.pdf
Aqilion is a Swedish life science company.
We believe the best source of new treatments comes from identifying, shaping and strengthening early drug innovation. We seek ideas that could potentially both improve patient quality of life and streamline health care.
We want to challenge and apply science in combination with creativity and entrepreneurship to maximize health care value for society.
Entries by Aqilion
Aqilion will attend the Nordic Female Investor Meet Up on the 15th of October in Malmö. Read more about the NFIM 2019 here:https://nfim19.confetti.events
Sarah Fredriksson, our CEO, will present Aqilion at the NLS Days 11 – 12 of September. We are looking forward to seeing you during the partnering event. Read more about NLS days:https://www.nlsdays.com
Aqilion identifies unique pharmaceutical projects at an early phase in the drug discovery process and develops them in preparation for clinical trials. The goal is to demonstrate the clinical and commercial potential of the medical innovation to attract industrial partners and buyers, who in turn have the capacity to continue clinical development and take the product to market.
The business model is based on involvement at an early stage and close collaboration with the innovator, regardless of whether the project is initiated by an external researcher, internal development project, or industrial partner.
Aqilion prefers projects aimed at niche markets. Specialty medications and orphan drugs are of particular interest.
Office Visiting Address
SE-252 20 Helsingborg